Marion Bertrand

Marion Bertrand

Auto-generated profile, based on publicly available information

Marion Bertrand

EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for the Safety of Medicines and Health Products (ANSM), French National Fund for Health Insurance (CNAM), Saint-Denis, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2022 in Annals of Internal Medicine
Verified
Journal Article
Open access
JBJérémie Botton
Jérémie Botton
MJMarie Joelle Jabagi
Marie Joelle Jabagi
MBMarion Bertrand
Marion Bertrand
BBBérangère Baricault
Bérangère Baricault
JDJérôme Drouin
Jérôme Drouin
RDRosemary Dray-Spira
Rosemary Dray-Spira
Severe cardiovascular events (myocardial infarction [MI], pulmonary embolism [PE], and stroke) have been reported after COVID-19 vaccination. In this French registry-based analysis of adults younge... Visual Risk for MI, Stroke, and PE Following COVID-19 Vaccines. Severe cardiovascular events (myocardial infarction [MI], pulmonary embolism [PE], and stroke) have been reported after COVI... Background: The BNT162b2 (Pfizer–BioNTech) vaccine has been shown to be safe with regard to risk for severe cardiovascular events (such as myocardial infarction [MI], pulmonary embolism [PE], and s...

25 February 2025 in NEJM Evidence
Verified
Journal Article
Closed access
MJMarie Joelle Jabagi
Marie Joelle Jabagi
JCJérémie F. Cohen
Jérémie F. Cohen
MBMarion Bertrand
Marion Bertrand
MCMartin Chalumeau
Martin Chalumeau
MZMahmoud Zureik
Mahmoud Zureik
In pivotal trials, nirsevimab showed promising efficacy in reducing hospitalizations for respiratory syncytial virus-associated lower respiratory tract infections (RSV-LRTIs). Nirsevimab's real-world effectiveness needs to be assessed. This population-based study used the French National Health Data System. All infants born between February 6 and September 15, 2023 were eligible. Each day during the study period (September 15, 2023, to January 31, 2024), all infants newly passively immunized with nirsevimab were matched to unimmunized controls in a 1:1 ratio according to sex, birth month, gestational age, department of residence, and the French Social Deprivation Index (Fdep). Study outcomes included RSV-LRTI-related hospitalization, RSV-LRTI necessitating admission to a pediatric intensive care unit (PICU) or high dependency unit (HDU), and RSV-LRTI requiring ventilation support or oxygen therapy. We estimated nirsevimab effectiveness using propensity score-weighted conditional Cox models. The study included 82,474 infants (41,237 in each group) with a median follow-up of 118 days (interquartile range, 76 to 125). The population included predominantly male infants (52.5%) born at term (94.6%), mostly between April and July 2023 (64.0%), and from more advantaged municipalities (FDep first quintile: 29.8%). In total, 342 infants (0.8%) in the nirsevimab group and 992 (2.4%) in the unimmunized group were hospitalized for RSV-LRTI. Nirsevimab's effectiveness was 65% (95% confidence interval [CI], 61 to 69) for RSV-LRTI hospitalizations; 74% (95% CI, 56 to 85) for RSV-LRTI PICU admissions; 64% (95% CI, 55 to 71) for RSV-LRTI HDU admissions; 66% (95% CI, 51 to 76) for RSV-LRTI hospitalization requiring ventilation support; and 67% (95% CI, 57 to 75) for RSV-LRTI hospitalization requiring oxygen therapy. Subgroup and sensitivity analyses yielded consistent effectiveness estimates. This study in a nationwide monoclonal antibody infusion setting suggests that a single injection of nirsevimab was associated with substantial protection of infants against hospitalization for RSV-LRTI.

21 June 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
KBKim Bouillon
Kim Bouillon
BBBérangère Baricault
Bérangère Baricault
LSLaura Semenzato
Laura Semenzato
JBJérémie Botton
Jérémie Botton
MBMarion Bertrand
Marion Bertrand
MZMahmoud Zureik
Mahmoud Zureik
Background: There is little evidence on the relationship between statin use and the risk of hospitalization attributable to COVID‐19. Methods and Results: The French National Healthcare Data System database was used to conduct a matched‐cohort study. For each adult aged ≥40 years receiving statins for the primary prevention of cardiovascular diseases, one nonuser was randomly selected and matched for year of birth, sex, residence area, and comorbidities. The association between statin use and hospitalization for COVID‐19 was examined using conditional Cox proportional hazards models, adjusted for baseline characteristics, comorbidities, and long‐term medications. Its association with in‐hospital death from COVID‐19 was also explored. All participants were followed up from February 15, 2020, to June 15, 2020. The matching procedure generated 2 058 249 adults in the statin group and 2 058 249 in the control group, composed of 46.6% of men with a mean age of 68.7 years. Statin users had a 16% lower risk of hospitalization for COVID‐19 than nonusers (adjusted hazard ratio [HR], 0.84; 95% CI, 0.81–0.88). All types of statins were significantly associated with a lower risk of hospitalization, with the adjusted HR ranging from 0.75 for fluvastatin to 0.89 for atorvastatin. Low‐ and moderate‐intensity statins also showed a lower risk compared with nonusers (HR, 0.78 [95% CI, 0.71–0.86] and HR, 0.84 [95% CI, 0.80–0.89], respectively), whereas high‐intensity statins did not (HR, 1.01; 95% CI, 0.86–1.18). We found similar results with in‐hospital death from COVID‐19. Conclusions: Our findings support that the use of statins for primary prevention is associated with lower risks of hospitalization for COVID‐19 and of in‐hospital death from COVID‐19.

11 February 2025 in BioDrugs
Verified
Journal Article
Closed access
PDF file
NHNadia Haddy
Nadia Haddy
HJHugo Jourdain
Hugo Jourdain
DDDavid Desplas
David Desplas
MBMarion Bertrand
Marion Bertrand
MJMarie Joelle Jabagi
Marie Joelle Jabagi
MZMahmoud Zureik
Mahmoud Zureik

1 May 2018 in Obstetrical & Gynecological Survey
Verified
Journal Article
Open access
PDF file
KBKim Bouillon
Kim Bouillon
MBMarion Bertrand
Marion Bertrand
GBGeorges Bader
Georges Bader
JLJean-Philippe Lucot
Jean-Philippe Lucot
RDRosemary Dray-Spira
Rosemary Dray-Spira
MZMahmoud Zureik
Mahmoud Zureik
(Abstracted from JAMA 2018;319:375–387) The main types of female sterilization in developed countries are laparoscopic and hysteroscopic sterilization. Approximately 1 million women worldwide have undergone the hysteroscopic procedure.

1 August 2022 in medRxiv
Verified
Preprint
Open access
PDF file
SVStéphane Le Vu
Stéphane Le Vu
MBMarion Bertrand
Marion Bertrand
MJMarie Joelle Jabagi
Marie Joelle Jabagi
JBJérémie Botton
Jérémie Botton
AWAlain Weill
Alain Weill
MZMahmoud Zureik
Mahmoud Zureik
Covid-19 mRNA vaccines have been shown to be associated with a short-term increased risk of myocarditis, with the highest risk observed after the second dose compared to the first. The extent of the risk associated with more distant booster doses is less clear. Here, we aimed to assess the relation between dosing interval and the risk of myocarditis, for both the two-dose primary series and the third dose (first booster). Extending our previous matched case-control study, we included 4 890 cases of myocarditis aged 12 or more and 48 900 controls up to January 31, 2022. We found that the risk of myocarditis remained elevated after the booster dose and that longer intervals between each consecutive dose (including booster doses) may decrease the occurrence of vaccine-associated myocarditis.